AOD-9604 vs Tesamorelin

AOD-9604 wins for: safety profile (near-placebo side effects), zero impact on GH/IGF-1/glucose, ease of stacking with other peptides, and discrete, modest fat loss with no HPTA disruption. Perfect for mild, targeted lipolysis and for users wanting 'HGH cutting signal' without metabolic or hormonal baggage.

Tesamorelin wins for: raw potency in reducing visceral (deep abdominal) and hepatic fat, clinically-validated effect size, and effective use in advanced recomposition (GH gut reversal, NAFLD cleanup). If you need heavy-duty VAT loss, tesamorelin is the only non-HGH peptide with credible human data, but you must monitor glucose, IGF-1, and side effects possible with full-axis GH manipulation.

Pick AOD-9604 if:

• You want subtle, sustained fat loss focused on stubborn depots (abdomen, flanks) with zero GH axis or insulin resistance risk.
• You're stacking alongside other peptides (CJC-1295, ipamorelin) or GLP-1s and want a side-effect-free lipolytic boost.
• Female users looking for safe, non-hormonal fat-loss support (identical protocol, no impact on menstrual cycle).
• You want no PCT, bloodwork, or cycle shutdown to worry about.
• You're averse to any metabolic side effects or have a history of glucose intolerance.

Pick Tesamorelin if:

• You need to specifically target visceral (deep-belly) and liver fat — e.g., after a long bulk, visible GH gut, or flagged NAFLD markers.
• You want MRI-proven, clinically-validated VAT reduction in the shortest time window.
• You're running high-dose AAS, GH, or insulin and need to reverse metabolic blowback (central fat, fatty liver).
• You don't mind managing mild GH/IGF-1 elevation and tracking glucose or fasting insulin during a long cycle.
• You're looking for a tool that mechanistically acts via your own GH axis, for deeper metabolic cleanup than cosmetic trimming.